source
- Alkermes reports Phase 3 success for Lumryz; Boehringer announces antibody partnershipAlkermes announced that its narcolepsy medication Lumryz, which received regulatory approval in 2023, achieved its primary efficacy endpoint in a Phase 3 trial. The study met the predefined criter…
- Pharma leaders risk industry collapse by over-relying on Chinese drug sourcing, says analystOlivia Kosloff, a senior fellow at the American Economic Liberties Project and co-chair of a Council on Foreign Relations working group, argues that U.S. pharma and biotech executives are jeopardiz…